MA45890B2 - Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes - Google Patents

Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes

Info

Publication number
MA45890B2
MA45890B2 MA45890A MA45890A MA45890B2 MA 45890 B2 MA45890 B2 MA 45890B2 MA 45890 A MA45890 A MA 45890A MA 45890 A MA45890 A MA 45890A MA 45890 B2 MA45890 B2 MA 45890B2
Authority
MA
Morocco
Prior art keywords
patient
pharmaceutical composition
opioid addiction
composition
preventing opioid
Prior art date
Application number
MA45890A
Other languages
English (en)
Other versions
MA45890A1 (fr
Inventor
Catherine Stehman-Breen
John Davis
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA45890A1 publication Critical patent/MA45890A1/fr
Publication of MA45890B2 publication Critical patent/MA45890B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une composition pharmaceutique destinée à prévenir une dépendance aux opioïdes chez un patient. La composition peut être utilisée chez un patient souffrant de lombalgie (lbp) modérée à sévère. La composition est avantageuse chez un patient ayant reçu un diagnostic de lombalgie, et comprend une quantité thérapeutiquement efficace d'un anticorps qui se lie plus particulièrement au facteur de croissance nerveuse (ngf) ou d'un fragment de liaison à l'antigène de ce dernier; et elle est utilisée en l'absence d'un opioïde servant à atténuer la douleur, et prévient la dépendance aux opioïdes chez un patient.
MA45890A 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes MA45890B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427365P 2016-11-29 2016-11-29
PCT/US2017/063417 WO2018102294A1 (fr) 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes

Publications (2)

Publication Number Publication Date
MA45890A1 MA45890A1 (fr) 2020-02-28
MA45890B2 true MA45890B2 (fr) 2022-10-31

Family

ID=60766150

Family Applications (2)

Application Number Title Priority Date Filing Date
MA45890A MA45890B2 (fr) 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
MA046951A MA46951A (fr) 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA046951A MA46951A (fr) 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes

Country Status (17)

Country Link
US (2) US10736961B2 (fr)
EP (1) EP3548082B1 (fr)
JP (1) JP7071975B2 (fr)
KR (1) KR20190090820A (fr)
CN (1) CN110072549A (fr)
AU (1) AU2017366870B2 (fr)
BR (1) BR112019010331A2 (fr)
CL (1) CL2019001385A1 (fr)
CO (1) CO2019005247A2 (fr)
EA (1) EA201991283A9 (fr)
IL (1) IL266640B (fr)
MA (2) MA45890B2 (fr)
MX (1) MX2019006013A (fr)
MY (1) MY200701A (fr)
PH (1) PH12019501087A1 (fr)
WO (1) WO2018102294A1 (fr)
ZA (1) ZA201902967B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210043624A (ko) * 2018-08-10 2021-04-21 리제너론 파아마슈티컬스, 인크. 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물
WO2023092052A1 (fr) 2021-11-19 2023-05-25 Regeneron Pharmaceuticals, Inc. Méthodes et compositions pour réduire la douleur centralisée
US20240002491A1 (en) 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
PL2187964T3 (pl) * 2007-08-10 2015-03-31 Regeneron Pharma Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).

Also Published As

Publication number Publication date
PH12019501087A1 (en) 2019-08-19
JP2019535716A (ja) 2019-12-12
MY200701A (en) 2024-01-11
JP7071975B2 (ja) 2022-05-19
MA46951A (fr) 2019-10-09
MX2019006013A (es) 2019-10-14
IL266640A (en) 2019-07-31
AU2017366870A1 (en) 2019-06-06
AU2017366870B2 (en) 2024-09-19
US20210060159A1 (en) 2021-03-04
CO2019005247A2 (es) 2019-05-31
WO2018102294A1 (fr) 2018-06-07
CA3045116A1 (fr) 2018-06-07
IL266640B (en) 2022-09-01
CN110072549A (zh) 2019-07-30
CL2019001385A1 (es) 2019-07-26
MA45890A1 (fr) 2020-02-28
US11491222B2 (en) 2022-11-08
US20180147280A1 (en) 2018-05-31
US10736961B2 (en) 2020-08-11
BR112019010331A2 (pt) 2019-10-22
EA201991283A1 (ru) 2019-09-30
EA201991283A9 (ru) 2019-11-27
KR20190090820A (ko) 2019-08-02
EP3548082A1 (fr) 2019-10-09
ZA201902967B (en) 2024-10-30
EP3548082B1 (fr) 2024-05-15

Similar Documents

Publication Publication Date Title
Kasperkiewicz et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients
MA33724B1 (fr) Anticorps neutralisants anti-ngf humain en tant qu'inhibiteurs selectifs de la voie du ngf
MA52962B1 (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
EA201170157A1 (ru) Notch-связывающие агенты и антагонисты и способы их применения
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
MA44234B1 (fr) Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3
CR20210492A (es) ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA33387B1 (fr) Polypeptides et procede de traitement
RU2017145653A (ru) Средства, пути применения и способы лечения синуклеопатии
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
MA38161A1 (fr) Anticorps anti-bmp-6
MA62992B1 (fr) Formulations de capsules
MA45890A1 (fr) Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
MA61946B1 (fr) Anticorps capables de se lier à la protéine spike du coronavirus sars-cov-2
MX2024005430A (es) Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau.
MA44917B1 (fr) Anticorps ou son fragment de liaison d’antigènes apte a se lier au récepteur d'interleukine-6 de l'humain.
BRPI0414688A (pt) tratamento de doença respiratória com anti-receptor de il-2
AR111767A1 (es) Proteínas de unión al antígeno anti-jagged1
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation